Skip to main content
Erschienen in: Heart and Vessels 10/2019

Open Access 15.04.2019 | Correction

Correction to: Percutaneous transcatheter closure of high-risk patent foramen ovale in the elderly

verfasst von: Hiroya Takafuji, Shinobu Hosokawa, Riyo Ogura, Yoshikazu Hiasa

Erschienen in: Heart and Vessels | Ausgabe 10/2019

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN
Hinweise
The original article can be found online at https://​doi.​org/​10.​1007/​s00380-019-01379-0.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Correction to: Heart and Vessels https://​doi.​org/​10.​1007/​s00380-019-01379-0

In the original publication of the article, the below sentence were garbled.
A list of errata is as follows:
1.
In Abstract the sentence from “Between September 2012 and October 2018, 14 patients 60 years old with high-risk PFO underwent percutaneous closure to prevent recurrence of cerebrovascular events” is wrongly published, the correct sentence is as follows “Between September 2012 and October 2018, 14 patients ≥ 60 years old with high-risk PFO underwent percutaneous closure to prevent recurrence of cerebrovascular events”.
 
2.
In Introduction the sentence from “However, most studies did not include elderly patients (age 60 years)” is wrongly published, the correct sentence is as follows “However, most studies did not include elderly patients (age ≥ 60 years)”.
 
3.
In Methods under the section “Indication of percutaneous PFO closure and definition of high-risk PFO” the sentence from “If these TEE findings were confirmed, the brain–heart team consisting of an interventional cardiologist and neurologist discussed whether to perform percutaneous closure or medical follow-up, also taking into account each patient’s frailty and activities of daily living performance” is wrongly published, the correct sentence is as follows “If these TEE findings were confirmed, the brain–heart team consisting of an interventional cardiologist and neurologist discussed whether to perform percutaneous closure or medical follow-up, also taking into account each patient’s frailty and activities of daily living performance”.
The sentence starting from “Shunt bubble grade was classified according to the number of passing bubbles from the right to the left atrium: grade 0, none; grade 1, 1–5 bubbles; grade 2, 6–20 bubbles; grade 3, 20 bubbles” has been wrongly published, the correct sentence is as follows “Shunt bubble grade was classified according to the number of passing bubbles from the right to the left atrium: grade 0, none; grade 1, 1–5 bubbles; grade 2, 6–20 bubbles; grade 3,  ≥ 20 bubbles”.
Also the sentence from “We defined high-risk PFO as follows: (1) long tunnel 10 mm and PFO separation height 2 mm” to “We defined high-risk PFO as follows: (1) long tunnel ≥ 10 mm and PFO separation height ≥ 2 mm”.
 
4.
Methods
Medications after percutaneous PFO closure, the sentence from “After percutaneous PFO closure, medications were prescribed according to the interventional cardiologist and neurologist’s judgment.” Has been wrongly published, the correct sentence is as follows “After percutaneous PFO closure, medications were prescribed according to the interventional cardiologist and neurologist’s judgment”.
 
5.
In Table 2, the second column is wrongly published as “Long tunnel ≧ 0 mm (%)”, the correct line is “Long tunnel ≥ 10 mm (%)”. Also the column four is wrongly published as “Height ≧ 2 mm (%)” the correct sentence is as follows “Height ≥ 2 mm (%)”.
 
6.
In References some reference are published incorrectly, the correct reference is as follows,
1.
Mas JL, Derumeaux G, Guillon B, Massardier E, Hosseini H, Mechtouff L, Arquizan C, Béjot Y, Vuillier F, Detante O, Guidoux C, Canaple S, Vaduva C, Dequatre-Ponchelle N, Sibon I, Garnier P, Ferrier A, Timsit S, Robinet-Borgomano E, Sablot D, Lacour JC, Zuber M, Favrole P, Pinel JF, Apoil M, Reiner P, Lefebvre C, Guérin P, Piot C, Rossi R, Dubois-Randé JL, Eicher JC, Meneveau N, Lusson JR, Bertrand B, Schleich JM, Godart F, Thambo JB, Leborgne L, Michel P, Pierard L, Turc G, Barthelet M, Charles-Nelson A, Weimar C, Moulin T, Juliard JM, Chatellier G, CLOSE Investigators (2017) Patent foramen ovale closure or anticoagulation vs. antiplatelets after stroke. N Engl J Med 377:1011–1021.
 
2.
Søndergaard L, Kasner SE, Rhodes JF, Andersen G, Iversen HK, Nielsen-Kudsk JE, Settergren M, Sjöstrand C, Roine RO, Hildick-Smith D, Spence JD, Thomassen L, Gore REDUCE Clinical Study Investigators (2017) Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke. N Engl J Med 377:1033–1042.
 
8.
Hart RG, Diener HC, Coutts SB, Easton JD, Granger CB, O’Donnell MJ, Sacco RL, Connolly SJ, Cryptogenic Stroke/ESUS International Working Group (2014) Embolic strokes of undetermined source: the case for a new clinical construct. Lancet Neurol 13:429–438.
 
14.
Bayar N, Arslan Ş, Çağırcı G, Erkal Z, Üreyen ÇM, Çay S, Köklü E, Yüksel İÖ, Küçükseymen S (2015) Assessment of morphology of patent foramen ovale with transesophageal echocardiography in symptomatic and asymptomatic patients. J Stroke Cerebrovasc Dis 24:1282–1286.
 
19.
Spies C, Khandelwal A, Timmemanns I, Kavinsky CJ, Schräder R, Hijazi ZM (2008) Recurrent events following patent foramen ovale closure in patients above 55 years of age with presumed paradoxical embolism. Catheter Cardiovasc Interv 72:966–970.
 
26.
Wahl A, Jüni P, Mono ML, Kalesan B, Praz F, Geister L, Räber L, Nedeltchev K, Mattle HP, Windecker S, Meier B (2012) Long-term propensity score-matched comparison of percutaneous closure of patent foramen ovale with medical treatment after paradoxical embolism. Circulation 125:803–812.
 
 
The original article has been corrected.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
download
DOWNLOAD
print
DRUCKEN

Unsere Produktempfehlungen

e.Med Interdisziplinär

Kombi-Abonnement

Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

Metadaten
Titel
Correction to: Percutaneous transcatheter closure of high-risk patent foramen ovale in the elderly
verfasst von
Hiroya Takafuji
Shinobu Hosokawa
Riyo Ogura
Yoshikazu Hiasa
Publikationsdatum
15.04.2019
Verlag
Springer Japan
Erschienen in
Heart and Vessels / Ausgabe 10/2019
Print ISSN: 0910-8327
Elektronische ISSN: 1615-2573
DOI
https://doi.org/10.1007/s00380-019-01408-y

Weitere Artikel der Ausgabe 10/2019

Heart and Vessels 10/2019 Zur Ausgabe

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.